3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Paraganglioma
6
Meningioma
6
Pheochromocytoma
5
Neuroendocrine Tumors
4
Neuroblastoma
3
Medulloblastoma
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Sarcoma, Synovial
1
Recurrence
1
Pituitary Neoplasms
1
Parathyroid Neoplasms
1
Osteosarcoma
1
Neoplasms, Germ Cell and Embryonal
1
Hypertension
1
Gastro-enteropancreatic neuroendocrine tumor
1
Esthesioneuroblastoma, Olfactory
1
Diffuse Intrinsic Pontine Glioma
1
Central Nervous System Neoplasms
1
Carcinoma, Medullary
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
2
Fluorodeoxyglucose F18
2
FAPI-46
2
pertuzumab
1
olaparib
1
lutetium Lu 177 dotatate
1
Quality of Life
1
Patient Reported Outcome Measures
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Immunotherapy
1
Erlotinib Hydrochloride
1
Drug Therapy
1
Biological Therapy
1
(18F)GTP1
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adrenal Gland Neoplasms
×
lutetium Lu 177 dotatate
×
CNS
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled